Enclomiphene Citrate vs Jatenzo: Real-World Evidence Comparison

What Are These Two Drugs and How Do They Work?

Enclomiphene citrate and Jatenzo address low testosterone through entirely different mechanisms. Enclomiphene is the trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM) that blocks estrogen receptors in the hypothalamus and pituitary, causing the brain to release more LH and FSH, which then drives testicular testosterone production. Jatenzo delivers testosterone directly, bypassing the hypothalamic-pituitary axis entirely.

Enclomiphene Citrate: Mechanism and Pharmacology

Enclomiphene acts upstream. By blocking estrogen-negative feedback at the hypothalamus, it raises gonadotropin secretion [1]. LH rises first, stimulating Leydig cell testosterone production, followed by FSH-driven support of spermatogenesis. Mean serum testosterone in a Phase II trial by Kim et al. (BJU Int 2016, N=124) rose from approximately 251 ng/dL at baseline to 461 ng/dL at 3 months on 12.5 mg/day and to 508 ng/dL on 25 mg/day [1]. Critically, sperm concentrations were maintained or improved in both dose groups, unlike clomiphene citrate where the cis-isomer (zuclomiphene) accumulates and may suppress spermatogenesis over time [2].

Because enclomiphene is not FDA-approved for male hypogonadism, every prescription issued today is off-label. Physicians typically prescribe it through compounding pharmacies [3].

Jatenzo: Mechanism and Pharmacology

Jatenzo (testosterone undecanoate 237 mg soft-gel capsule) is absorbed via intestinal lymphatics, bypassing first-pass hepatic metabolism [4]. The FDA approved it in June 2019 for adult males with hypogonadism due to an organic cause. In the key trial reported by Swerdloff et al. (J Clin Endocrinol Metab 2020, N=166), 87% of participants achieved average testosterone concentrations (C-avg) in the normal range (300-1000 ng/dL) at the 90-day primary endpoint when dosed at 237 mg BID [5]. Mean C-avg was 520 ng/dL. The drug does not require refrigeration and is taken twice daily with a meal containing at least 30 grams of fat to maximize lymphatic absorption [4].

Clinical Trial Evidence: Head-to-Head Data and What Real Studies Show

No randomized controlled trial has directly compared enclomiphene citrate with Jatenzo in the same population. Evidence must be synthesized across separate trials conducted in different cohorts under different protocols.

Efficacy: Testosterone Normalization Rates

In Kim et al. (N=124), enclomiphene 25 mg/day normalized total testosterone (defined as >300 ng/dL) in approximately 78% of men at 3 months, with mean testosterone reaching 508 ng/dL [1]. Sperm concentration was 33.0 million/mL at baseline and 31.0 million/mL at 3 months, confirming no meaningful spermatogenic suppression.

In Swerdloff et al. (N=166), Jatenzo 237 mg BID achieved the primary endpoint (C-avg 300-1000 ng/dL) in 87% of participants at Day 90 [5]. Mean C-avg was 520 ng/dL. The trial also measured maximum concentration (C-max), which averaged 1294 ng/dL, raising some concerns about short-term supraphysiologic peaks [5].

Taken together, normalization rates appear broadly similar (78% vs 87%), but the populations, testosterone definitions, and measurement methods differ enough that a direct percentage comparison has limited meaning.

Gonadotropin and Fertility Outcomes

Enclomiphene raises LH and FSH as part of its mechanism. In the Kim trial, mean LH rose from 4.2 IU/L to 7.3 IU/L on 25 mg/day and FSH rose from 5.1 IU/L to 8.6 IU/L [1]. This gonadotropin elevation is precisely what makes enclomiphene attractive for men with secondary hypogonadism who wish to preserve or restore fertility [2].

Jatenzo, like all exogenous testosterone preparations, suppresses LH and FSH through negative feedback [4]. Spermatogenesis is therefore impaired during treatment. Men who stop Jatenzo may experience a recovery period of 3-12 months before gonadotropins and sperm counts normalize, though recovery timelines vary considerably [6].

Symptom Relief and Patient-Reported Outcomes

Both agents improve symptoms of hypogonadism. A pooled analysis of enclomiphene studies showed improvements in IIEF (International Index of Erectile Function) scores and fatigue measures at 12 weeks, although these data come from relatively small trials [7]. Jatenzo's Phase III data showed improvements in Sexual Motivation subscale scores and energy levels at 90 days, mirroring benefits seen with other testosterone formulations [5].

Safety Profiles: Where the Two Drugs Differ Most

Safety is the sharpest point of differentiation between these two drugs.

Jatenzo's FDA Boxed Warning for Blood Pressure

Jatenzo carries an FDA boxed warning stating that it causes increases in blood pressure that may raise the risk of major adverse cardiovascular events (MACE) [4]. In the Swerdloff trial, mean systolic blood pressure increased by 3.9 mmHg at Day 90 [5]. The FDA label recommends measuring blood pressure before initiating Jatenzo, monitoring at 3 months, and then periodically thereafter. Men with uncontrolled hypertension should not start Jatenzo [4]. This warning does not appear on any other oral testosterone product because Jatenzo is the only FDA-approved oral testosterone formulation currently available in the United States [8].

Enclomiphene and Estrogen Elevation

Because enclomiphene raises LH and thus testosterone, it also raises aromatase substrate, which means estradiol tends to rise alongside testosterone [1]. In the Kim trial, mean estradiol increased from 20.1 pg/mL to 31.6 pg/mL on 25 mg/day [1]. Values remained within the typical male reference range (<42 pg/mL), but some men experience gynecomastia, nipple sensitivity, or mood changes if estradiol climbs above 40 pg/mL [9]. Periodic estradiol monitoring is reasonable, and dose reduction usually resolves the issue without requiring an aromatase inhibitor.

Hematologic Effects

Exogenous testosterone including Jatenzo raises hematocrit through erythropoietic stimulation [4]. The Swerdloff trial reported polycythemia (hematocrit >54%) in 7.1% of participants at some point during treatment [5]. Enclomiphene also raises testosterone, so mild hematocrit elevation is possible, though the effect is generally smaller because endogenous testosterone levels tend to plateau at physiologic rather than supraphysiologic values [1]. The Endocrine Society guideline recommends monitoring hematocrit at 3-6 months after initiating any testosterone therapy and annually thereafter [10].

Hepatic Safety

Older oral androgens (notably 17-alpha-alkylated steroids) carried significant hepatotoxicity risk. Jatenzo avoids this through lymphatic absorption, and no clinically meaningful hepatotoxicity signal appeared in its trials [4][5]. Enclomiphene is a SERM, not an anabolic steroid, and hepatotoxicity has not been reported in clinical-grade formulations [7].

Who Is Each Drug Best For?

Patient selection determines which agent delivers better outcomes. Neither drug is universally superior.

Men Who Should Consider Enclomiphene Citrate

Enclomiphene is well-suited for men with secondary (hypogonadotropic) hypogonadism who want to father children now or in the future [2]. Because it preserves the HPG axis, it also maintains testicular size and function, which many men report as a quality-of-life priority [1]. Men who are averse to injection-based TRT but are also not candidates for exogenous testosterone due to fertility concerns often use enclomiphene as a bridge or long-term solution.

Men with mild-to-moderate testosterone deficiency (total T between 200-350 ng/dL) and preserved pituitary function tend to respond best. Men with primary hypogonadism (elevated LH/FSH at baseline, Klinefelter syndrome, prior testicular damage) will not respond because the testes cannot respond to increased gonadotropin stimulation [2].

Men Who Should Consider Jatenzo

Jatenzo suits men who have confirmed hypogonadism due to an organic cause, have no fertility plans, prefer oral over injectable or transdermal delivery, and have well-controlled blood pressure [4][5]. The twice-daily dosing with fatty food is a real adherence barrier for some patients, but for men who already take medications with meals, the routine is manageable.

Men with uncontrolled hypertension, pre-existing cardiovascular disease requiring strict blood pressure management, or those with elevated baseline hematocrit (>50%) are poor candidates for Jatenzo based on its labeled contraindications and warnings [4].

Switching From Enclomiphene Citrate to Jatenzo: Clinical Considerations

Some men start on enclomiphene and later transition to Jatenzo after completing family planning or when enclomiphene no longer produces adequate testosterone response.

Why Men Switch

The most common reason is incomplete efficacy. If baseline LH and FSH are not low, enclomiphene has limited ability to push testosterone above 400-500 ng/dL in some men [7]. Men whose symptoms persist despite testosterone levels in the low-normal range sometimes require higher steady-state testosterone, which Jatenzo can deliver more reliably. Completed fertility goals also remove the primary argument for preserving the HPG axis, making exogenous testosterone more acceptable.

How to Transition Safely

When stopping enclomiphene and starting Jatenzo, no washout period is strictly required because enclomiphene has a half-life of approximately 10 days for the active trans-isomer [1]. A physician should obtain a baseline blood pressure reading, complete blood count, lipid panel, and serum testosterone before the first Jatenzo dose [4]. The starting dose of Jatenzo is 237 mg BID with food; the FDA label permits titration to 158 mg BID if the patient overshoots target range or to 396 mg BID if testosterone remains sub-therapeutic at the 90-day check [4].

Men should expect their LH and FSH to decline substantially within 4-6 weeks of starting Jatenzo as exogenous testosterone suppresses gonadotropin secretion. Testicular volume may decrease over several months [6].

Monitoring After the Switch

The Endocrine Society's 2018 Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism recommends checking serum testosterone 3-6 months after initiating therapy, hematocrit at 3-6 months, and PSA at 3-12 months in men over 40 [10]. Blood pressure monitoring is additionally required for Jatenzo per its boxed warning, with a mandatory check at 3 months after the first dose [4]. A structured monitoring schedule for a man transitioning from enclomiphene to Jatenzo would therefore include: blood pressure at weeks 4 and 12, total and free testosterone at week 12 (trough, before morning dose), hematocrit at week 12, and a lipid panel at week 12 because testosterone modestly reduces HDL [5][10].

Cost, Access, and Insurance Coverage

Neither drug is inexpensive, and insurance coverage is inconsistent for both.

Enclomiphene Citrate Cost and Availability

Enclomiphene citrate is not FDA-approved for hypogonadism, so it is dispensed almost exclusively through compounding pharmacies. Cash prices range from approximately $50-150 per month depending on dose and pharmacy. It is not covered by most commercial insurance plans, and Medicare does not cover compounded drugs [3]. Telehealth platforms including HealthRX that prescribe enclomiphene are prescribing it off-label, which is legal but means the formulation and quality standards differ from FDA-approved manufacturing.

Jatenzo Cost and Insurance Coverage

Jatenzo's retail price without insurance is approximately $550-700 per month for the 237 mg dose based on 2024 pharmacy data [11]. A manufacturer savings card (Endo Pharmaceuticals) may reduce out-of-pocket cost for commercially insured patients to as low as $0/month, but eligibility depends on plan type and income [11]. Medicare Part D generally does not cover testosterone for hypogonadism unless the diagnosis qualifies under specific plan criteria [12].

Pharmacist and Prescriber Practical Points

Prescribers who manage both drugs routinely note several real-world nuances that trial data do not fully capture.

Food Requirement for Jatenzo

Jatenzo's lymphatic absorption depends on dietary fat. In the key trial, patients were instructed to take each dose with a meal or snack containing at least 30 grams of fat [5]. A missed-fat meal can reduce testosterone exposure by up to 35%, meaning skipped breakfast or low-fat diets substantially undermine efficacy [4]. Patients who travel frequently, skip breakfast, or follow low-fat diets for cardiovascular reasons are at highest risk of subtherapeutic levels.

Compounding Quality Variability for Enclomiphene

Because enclomiphene is compounded rather than manufactured under NDA standards, potency and purity can vary between pharmacies [3]. The FDA has issued guidance warning that the active pharmaceutical ingredient (API) used in compounded testosterone products must meet USP standards [3]. Prescribers should direct patients to PCAB-accredited compounding pharmacies and advise that generic equivalence assumptions do not apply.

Drug Interactions

Jatenzo is a substrate of CYP3A4. Concurrent use of strong CYP3A4 inhibitors (ketoconazole, clarithromycin) can raise testosterone concentrations unexpectedly [4]. Enclomiphene has no well-characterized CYP drug interactions at clinical doses, though it competes at estrogen receptors, so co-administration with SERMs or aromatase inhibitors requires careful monitoring [7]. Both agents may potentiate the anticoagulant effect of warfarin; INR should be checked within 2-3 weeks of starting either drug in anticoagulated patients [4][10].

What the Evidence Does Not Tell Us

Long-Term Cardiovascular Data Are Limited for Both

The Jatenzo key trial ran 365 days; the Kim enclomiphene trial ran 3 months [1][5]. Long-term cardiovascular outcomes data for either agent are sparse. The TRAVERSE trial (N=5,204, median follow-up 33 months) evaluated non-inferiority of testosterone replacement therapy vs placebo for MACE in men with hypogonadism and established or high risk of cardiovascular disease, and found testosterone was non-inferior to placebo for the primary MACE endpoint [13]. TRAVERSE did not study oral testosterone undecanoate or enclomiphene specifically, but it provides the most relevant long-term safety context available for TRT in cardiovascular risk patients [13].

Comparative Bone Density and Body Composition Data Are Absent

Testosterone improves bone mineral density and lean mass. Neither agent has been tested head-to-head for these endpoints. Jatenzo's Phase III trial measured body composition at 365 days and found a mean lean mass increase of 3.1 kg and fat mass decrease of 2.5 kg [5]. Comparable long-term body composition data for enclomiphene do not exist in the published literature as of mid-2025 [7].

Regulatory and Guideline Context

The Endocrine Society's 2018 Clinical Practice Guideline states: "We suggest using testosterone therapy in men with hypogonadism to induce and maintain secondary sex characteristics and correct symptoms" and specifies that treatment choice should account for formulation preference, cost, and fertility intent [10]. The guideline does not recommend enclomiphene by name for hypogonadism but acknowledges off-label use of clomiphene in men who desire fertility preservation [10].

The American Urological Association's 2018 Guideline on Evaluation and Management of Testosterone Deficiency similarly notes that clomiphene and its analogs may preserve fertility while raising testosterone, but characterizes the evidence base as lower quality compared to approved testosterone formulations [14]. Enclomiphene had not completed its FDA NDA review for hypogonadism as of 2025, and the FDA issued a Complete Response Letter to Repros Therapeutics regarding its enclomiphene application, citing the need for additional safety and efficacy data [15].

Jatenzo's label was updated by the FDA in 2022 to strengthen the blood pressure boxed warning language, reflecting post-marketing blood pressure surveillance data [8].